# Jan Van den Bossche

> Jan Van den Bossche is a Series B investor at Andera Partners backing Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners)
- Location: Paris, France
- Total investments: 4
- Last investment: Jan 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jan-van-den-bossche-aa68974

Jan Van den Bossche is a Series B investor at Andera Partners in Paris focused on Health Care and Biotechnology. Jan Van den Bossche is based out of Paris, Île-de-France, and is the Partner at Andera Partners and Board of Director at Alveus Therapeutics. Jan previously served as the Member Board Of Directors at Cardior Pharmaceuticals. Jan Van den Bossche attended KU Leuven.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Diabetes | 1 | 25% |
| Life Science | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |
| Series C | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 25% |
| Germany | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $63.2M | Series B | May 03, 2022 |  |
| Indigo Diabetes | Indigo Diabetes nv (Indigo) is a young high-tech medical device company founded by Danaë Delbeke and her team ended in 2016. Indigo develops the world’s first invisible sensor for people living with diabetes to address their need for accurate glucose monitoring with improved user experience. Indigo exploits groundbreaking photonics technology thatrevolutionized the Internet during the last decades and now aims at transforming diabetes management. | $44.7M | Series B | Jul 27, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 2 deals together
- [OCCIDENT](https://shizune.co/investors/profile/occident-group) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [Ackermans & van Haaren](https://shizune.co/investors/profile/ackermans-van-haaren) — VC Fund, 1 deal together
- [Ascenta Capital](https://shizune.co/investors/profile/ascenta-capital) — VC Fund, 1 deal together

## About Andera Partners

VC Fund · Paris, France

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

5 contacts available at Andera Partners.

| Name | Title | Profile |
| --- | --- | --- |
| François Boudreault | Censor | https://shizune.co/investors/profile/franois-boudreault |
| Francois Xavier Mauron | Partner | https://shizune.co/investors/profile/francois-xavier-mauron |
| Gilles Nobecourt | Partner | https://shizune.co/investors/profile/gilles-nobecourt |
| Guillem Laporta | Analyst | https://shizune.co/investors/profile/guillem-laporta |
| Jan Van den Bossche | Partner | https://shizune.co/investors/profile/jan-van-den-bossche |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Jan Van den Bossche invest in?

Jan Van den Bossche invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jan Van den Bossche last invest?

The most recent investment recorded for Jan Van den Bossche closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co